Skip to content
Menu

JP Morgan Maintains Overweight on Abbott Laboratories, Lowers Price Target to $118

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice TargetHot

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.

JP Morgan analyst Robbie Marcus maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $120 to $118.

Read at benzinga.com

← All stock news